Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug
Bad news from FDA prompts Spero to lay off 75% [...]
Bad news from FDA prompts Spero to lay off 75% [...]
After a dismal last year, Sesen Bio grasps for alternatives [...]
As expected, FDA spikes down Axsome migraine med, but issues [...]
Biogen takes another dip into Scribe gene therapy collab with [...]
Patient Square Capital invests $300M to support ‘golden age of [...]
Human testing for Praxis’ lead epilepsy drug held up after [...]
AstraZeneca will have to wait a little longer for fruit [...]
AbbVie’s cystic fibrosis long-game doesn’t pay off, as Galapagos med [...]
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new [...]
Genocea’s Atlas no longer holding up sky, as biotech moves [...]